EP0804181A4 - Method and composition for treating mammalian diseases caused by inflammatory response - Google Patents

Method and composition for treating mammalian diseases caused by inflammatory response

Info

Publication number
EP0804181A4
EP0804181A4 EP96929932A EP96929932A EP0804181A4 EP 0804181 A4 EP0804181 A4 EP 0804181A4 EP 96929932 A EP96929932 A EP 96929932A EP 96929932 A EP96929932 A EP 96929932A EP 0804181 A4 EP0804181 A4 EP 0804181A4
Authority
EP
European Patent Office
Prior art keywords
composition
inflammatory response
diseases caused
treating mammalian
mammalian diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96929932A
Other languages
German (de)
French (fr)
Other versions
EP0804181A1 (en
Inventor
Stanley E Katz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellular Sciences Inc
Original Assignee
Cellular Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Sciences Inc filed Critical Cellular Sciences Inc
Publication of EP0804181A1 publication Critical patent/EP0804181A1/en
Publication of EP0804181A4 publication Critical patent/EP0804181A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96929932A 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response Withdrawn EP0804181A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US396295P 1995-09-19 1995-09-19
PCT/US1996/014304 WO1997010818A1 (en) 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response

Publications (2)

Publication Number Publication Date
EP0804181A1 EP0804181A1 (en) 1997-11-05
EP0804181A4 true EP0804181A4 (en) 2005-02-02

Family

ID=21708422

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96929932A Withdrawn EP0804181A4 (en) 1995-09-19 1996-09-06 Method and composition for treating mammalian diseases caused by inflammatory response

Country Status (10)

Country Link
EP (1) EP0804181A4 (en)
JP (1) JP4459303B2 (en)
AU (1) AU719332B2 (en)
CA (1) CA2205112C (en)
IL (1) IL119225A (en)
MX (1) MX9703653A (en)
NZ (1) NZ306832A (en)
TW (1) TW434012B (en)
WO (1) WO1997010818A1 (en)
ZA (1) ZA967833B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4885362B2 (en) * 1999-05-14 2012-02-29 セルラー サイエンセズ インコーポレイテッド Methods and compositions for treating nasal and sinus diseases of mammals caused by an inflammatory response
AU2002255805B2 (en) * 2001-03-15 2005-03-24 North Shore Long Island Jewish Research Institute Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
US20030105162A1 (en) * 2001-08-21 2003-06-05 Celluar Sciences, Inc. Method for treating bronchial constriction and bronchospasm
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US6623723B2 (en) * 2001-08-21 2003-09-23 Cellular Sciences Inc. Method for treating bronchial constriction and bronchospasm
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
JP5630750B2 (en) * 2008-03-18 2014-11-26 国立大学法人 岡山大学 Excitatory chemical transmission regulator and screening method thereof
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease
JP2020524144A (en) * 2017-06-16 2020-08-13 ヴァンダービルト ユニヴァーシティ Methods and compositions for treating microbial inflammation
EP3797766A1 (en) * 2019-09-24 2021-03-31 Evonik Operations GmbH Compositions for use in reducing inflammation
CN114641562A (en) * 2019-11-14 2022-06-17 默克专利股份公司 Cell culture medium

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1857M (en) * 1962-03-08 1963-06-10 Roussel Uclaf New drug in particular for the treatment of diseases of viral origin.
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
US3920835A (en) * 1973-09-04 1975-11-18 Scott Eugene J Van Treatment of disturbed keratinization
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US4105783A (en) * 1975-07-23 1978-08-08 Yu Ruey J Therapeutic treatment of dry skin
US4158057A (en) * 1975-03-28 1979-06-12 Stanko Ronald T Prevention of the accumulation of fatty deposits in the liver
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
DE3302694A1 (en) * 1983-01-27 1984-08-02 Retheto Filmtechnik Theilemann & Co, 8000 München ORAL CARE PRODUCTS
US4521375A (en) * 1982-11-23 1985-06-04 Coopervision, Inc. Sterilizing treatment with hydrogen peroxide and neutralization of residual amounts thereof
US4663166A (en) * 1984-06-22 1987-05-05 Veech Richard L Electrolyte solutions and in vivo use thereof
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
JPS63135370A (en) * 1986-11-26 1988-06-07 Grelan Pharmaceut Co Ltd Antiallergic agent
EP0315467A2 (en) * 1987-11-06 1989-05-10 LyphoMed, Inc. Pentamidine salts useful in the treatment and prophylaxis of pneumocystis carinii pneumonia
WO1990000900A1 (en) * 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
JPH02124824A (en) * 1988-11-02 1990-05-14 Eisai Co Ltd Preparation for percutaneous application containing azelastine or slat thereof
WO1991015223A1 (en) * 1990-03-30 1991-10-17 Amgen Inc. Respiratory burst suppression factor
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
WO1993016690A1 (en) * 1992-02-25 1993-09-02 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
JPH05306218A (en) * 1992-04-27 1993-11-19 Kao Corp Bronchodilator
US5296370A (en) * 1990-10-04 1994-03-22 Rutgers, The State University Repair medium for the resuscitation of injured cells
WO1996000584A1 (en) * 1994-06-30 1996-01-11 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1857M (en) * 1962-03-08 1963-06-10 Roussel Uclaf New drug in particular for the treatment of diseases of viral origin.
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
US3920835A (en) * 1973-09-04 1975-11-18 Scott Eugene J Van Treatment of disturbed keratinization
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US4158057A (en) * 1975-03-28 1979-06-12 Stanko Ronald T Prevention of the accumulation of fatty deposits in the liver
US4105783A (en) * 1975-07-23 1978-08-08 Yu Ruey J Therapeutic treatment of dry skin
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
US4521375A (en) * 1982-11-23 1985-06-04 Coopervision, Inc. Sterilizing treatment with hydrogen peroxide and neutralization of residual amounts thereof
DE3302694A1 (en) * 1983-01-27 1984-08-02 Retheto Filmtechnik Theilemann & Co, 8000 München ORAL CARE PRODUCTS
US4663166A (en) * 1984-06-22 1987-05-05 Veech Richard L Electrolyte solutions and in vivo use thereof
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
US4725586A (en) * 1985-08-01 1988-02-16 Lindstrom Richard L Surgical solution
JPS63135370A (en) * 1986-11-26 1988-06-07 Grelan Pharmaceut Co Ltd Antiallergic agent
EP0315467A2 (en) * 1987-11-06 1989-05-10 LyphoMed, Inc. Pentamidine salts useful in the treatment and prophylaxis of pneumocystis carinii pneumonia
WO1990000900A1 (en) * 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
JPH02124824A (en) * 1988-11-02 1990-05-14 Eisai Co Ltd Preparation for percutaneous application containing azelastine or slat thereof
WO1991015223A1 (en) * 1990-03-30 1991-10-17 Amgen Inc. Respiratory burst suppression factor
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
US5296370A (en) * 1990-10-04 1994-03-22 Rutgers, The State University Repair medium for the resuscitation of injured cells
WO1993016690A1 (en) * 1992-02-25 1993-09-02 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
JPH05306218A (en) * 1992-04-27 1993-11-19 Kao Corp Bronchodilator
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
WO1996000584A1 (en) * 1994-06-30 1996-01-11 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
ACTA OTO-LARYNGOLOGICA. SUPPLEMENTUM. 1994, vol. 515, 1994, pages 18 - 21, ISSN: 0365-5237 *
BÜNGER R ET AL: "Pyruvate attenuation of hypoxia damage in isolated working guinea-pig heart.", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY. APR 1986, vol. 18, no. 4, April 1986 (1986-04-01), pages 423 - 438, XP008039899, ISSN: 0022-2828 *
COHEN J ET AL: "Pregnancies following the frozen storage of expanding human blastocysts.", JOURNAL OF IN VITRO FERTILIZATION AND EMBRYO TRANSFER : IVF. JUN 1985, vol. 2, no. 2, June 1985 (1985-06-01), pages 59 - 64, XP008039916, ISSN: 0740-7769 *
COHEN M H: "Cure of advanced L1210 leukemia after correction of abnormal red blood cell deformability.", CANCER CHEMOTHERAPY AND PHARMACOLOGY. 1981, vol. 5, no. 3, 1981, pages 175 - 179, XP008039915, ISSN: 0344-5704 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1994, WESTRIN K M ET AL: "Microorganisms and leukocytes in purulent sinusitis: a symbiotic relationship in metabolism.", XP002309523, Database accession no. NLM8067237 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; January 1986 (1986-01-01), PINE L ET AL: "Role of keto acids and reduced-oxygen-scavenging enzymes in the growth of Legionella species.", XP002309522, Database accession no. NLM3009529 *
DATABASE WPI Section Ch Week 198828, Derwent World Patents Index; Class B03, AN 1988-195837, XP002296174 *
DATABASE WPI Section Ch Week 199025, Derwent World Patents Index; Class B02, AN 1990-189693, XP002296176 *
DATABASE WPI Section Ch Week 199351, Derwent World Patents Index; Class B05, AN 1993-408833, XP002296175 *
DAVIS D L: "Culture and storage of pig embryos.", JOURNAL OF REPRODUCTION AND FERTILITY. SUPPLEMENT. 1985, vol. 33, 1985, pages 115 - 124, XP008039913, ISSN: 0449-3087 *
GIANNELLI S JR ET AL: "Prevention of increased hemoglobin-oxygen affinity in open-heart operations with inosine-phosphate-pyruvate solution.", THE ANNALS OF THORACIC SURGERY. MAY 1976, vol. 21, no. 5, May 1976 (1976-05-01), pages 386 - 396, XP008039903, ISSN: 0003-4975 *
JOURNAL OF CLINICAL MICROBIOLOGY. JAN 1986, vol. 23, no. 1, January 1986 (1986-01-01), pages 33 - 42, ISSN: 0095-1137 *
MARCHOK A C ET AL: "Increased in vitro growth capacity of tracheal epithelium exposed in vivo to 7, 12-dimethylbenz(a)anthracene.", CANCER RESEARCH. JUN 1977, vol. 37, no. 6, June 1977 (1977-06-01), pages 1811 - 1821, XP008039914, ISSN: 0008-5472 *
MENTZER R M JR ET AL: "Effect of pyruvate on regional ventricular function in normal and stunned myocardium.", ANNALS OF SURGERY. MAY 1989, vol. 209, no. 5, May 1989 (1989-05-01), pages 629 - 633 ; dis, XP008039900, ISSN: 0003-4932 *
MILLER W F: "Aerosol therapy in acute and chronic respiratory disease.", ARCHIVES OF INTERNAL MEDICINE. JAN 1973, vol. 131, no. 1, January 1973 (1973-01-01), pages 148 - 155, XP008039886, ISSN: 0003-9926 *
MOCHIZUKI S ET AL: "Energy metabolism during reperfusion following ischemia.", JOURNAL DE PHYSIOLOGIE. 1980, vol. 76, no. 7, 1980, pages 805 - 812, XP008039901, ISSN: 0021-7948 *
O'DONNELL-TORMEY J ET AL: "Secretion of pyruvate. An antioxidant defense of mammalian cells.", THE JOURNAL OF EXPERIMENTAL MEDICINE. 1 FEB 1987, vol. 165, no. 2, 1 February 1987 (1987-02-01), pages 500 - 514, XP002309326, ISSN: 0022-1007 *
OGAWA Y ET AL: "Comparative study of the effects of pyruvate and CG-120 in preventing experimental oxalate urolithiasis in rats.", HINYOKIKA KIYO. ACTA UROLOGICA JAPONICA. SEP 1986, vol. 32, no. 9, September 1986 (1986-09-01), pages 1341 - 1347, XP008039912, ISSN: 0018-1994 *
PUSCHMANN M ET AL: "[Double-blind controlled gastroscopic comparative study on lesions of the gastric mucosa in healthy volunteers after treatment with acetylsalicylic acid or acetylsalicylic acid/sodium pyruvate]", ARZNEIMITTEL-FORSCHUNG. 1983, vol. 33, no. 3, 1983, pages 415 - 416, XP008039938, ISSN: 0004-4172 *
PUSCHMANN M: "[Animal experiments on the gastric mucosa and demonstration of analgesic and antipyretic effects after combined administration of acetylsalicylic acid and sodium pyruvate]", ARZNEIMITTEL-FORSCHUNG. 1983, vol. 33, no. 3, 1983, pages 410 - 415, XP008039937, ISSN: 0004-4172 *
REGITZ V ET AL: "Biochemical mechanism of infarct size reduction by pyruvate.", CARDIOVASCULAR RESEARCH. NOV 1981, vol. 15, no. 11, November 1981 (1981-11-01), pages 652 - 658, XP008039902, ISSN: 0008-6363 *
SABRI M I ET AL: "EFFECT OF EXOGENOUS PYRUVATE ON ACRYLAMIDE NEUROPATHY IN RATS", BRAIN RESEARCH, AMSTERDAM, NL, vol. 483, no. 1, 1989, pages 1 - 11, XP001190880, ISSN: 0006-8993 *
SCHWARTZ C ET AL: "Antagonism of cyanide intoxication with sodium pyruvate.", TOXICOLOGY AND APPLIED PHARMACOLOGY. 30 SEP 1979, vol. 50, no. 3, 30 September 1979 (1979-09-30), pages 437 - 441, XP008039904, ISSN: 0041-008X *
See also references of WO9710818A1 *
SHACTER E: "Serum-free medium for growth factor-dependent and -independent plasmacytomas and hybridomas.", JOURNAL OF IMMUNOLOGICAL METHODS. 20 MAY 1987, vol. 99, no. 2, 20 May 1987 (1987-05-20), pages 259 - 270, XP008039984, ISSN: 0022-1759 *

Also Published As

Publication number Publication date
AU6915996A (en) 1997-04-09
AU719332B2 (en) 2000-05-04
ZA967833B (en) 1997-06-02
EP0804181A1 (en) 1997-11-05
MX9703653A (en) 1998-07-31
CA2205112A1 (en) 1997-03-27
CA2205112C (en) 2008-11-18
IL119225A (en) 2000-09-28
JPH10509463A (en) 1998-09-14
JP4459303B2 (en) 2010-04-28
IL119225A0 (en) 1996-12-05
WO1997010818A1 (en) 1997-03-27
NZ306832A (en) 2001-04-27
TW434012B (en) 2001-05-16

Similar Documents

Publication Publication Date Title
AU695664B2 (en) Method for treating cardiac inflammatory disease
CY2178B1 (en) Naphthyl compounds intermediates compositions and methods
IL123166A0 (en) Method and composition for treating asthma
PL323258A1 (en) Novel method of controlling biological degradation
AU4017395A (en) Method for treating anxiety
AU642762B2 (en) Method of treating inflammatory bowel disease
IL97973A0 (en) Composition and method for controlling cholesterol
NO981403D0 (en) Method and composition for controlling frogs using amides
GB2298713B (en) Method and composition
PL314996A1 (en) Kappa-opiatagonistic agents for treating intestinal inflammatory diseases
PL318193A1 (en) Novel streptogramines and method of obtaining them by mutasynthesis
AU1074397A (en) Method for treating anxiety
ZA967833B (en) Method and composition for treating mammalian diseases caused by inflammatory response
IL119817A0 (en) Liquid-absorbent article and method for its manufacture
PL327439A1 (en) Microbiological method of 11alpha- hydroxylating the steroids
ZA961226B (en) An apparatus and method to manufacture cast panels
AU7726396A (en) Method for treating anxiety
GB9410345D0 (en) Method of genetic testing
NO944995D0 (en) Method and apparatus for conditioning pre-material
AU7674796A (en) Method for treating anxiety
IL125043A0 (en) Iminooxyphenylacetic acid derivatives method and intermediates for their preparation and their use
HUP9602938A2 (en) Improved composition and method for acid gas treatment
IL123478A0 (en) Method and composition for the manufacture of ophthalmic lenses
AU4017195A (en) Method for treating anxiety
AU7999691A (en) Phthalamic acids and their isomers for treating leukotriene-related diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 11/00 B

Ipc: 7A 61K 31/16 B

Ipc: 7A 61K 31/047 B

Ipc: 7A 61K 31/12 B

Ipc: 7A 61K 31/195 B

Ipc: 7A 61K 31/19 A

A4 Supplementary search report drawn up and despatched

Effective date: 20041221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130403